NMBS-2 is under clinical development by Nimbus Therapeutics and currently in Phase II for Colon Cancer. According to GlobalData, Phase II drugs for Colon Cancer have an 11% phase transition success rate (PTSR) indication benchmark for progressing into Phase III. GlobalData’s report assesses how NMBS-2’s drug-specific PTSR and Likelihood of Approval (LoA) scores compare to the indication benchmarks. Buy the report here.

Smarter leaders trust GlobalData

GlobalData tracks drug-specific phase transition and likelihood of approval scores, in addition to indication benchmarks based off 18 years of historical drug development data. Attributes of the drug, company and its clinical trials play a fundamental role in drug-specific PTSR and likelihood of approval.

NMBS-2 overview

NMBS-2 is under development for the treatment of colorectal cancer, melanoma, colon cancer, pancreatic cancer, non-small cell lung cancer, renal cell carcinoma, endometrial cancer, breast carcinoma, advanced or metastatic gastric cancer, adenocarcinoma of the gastroesophageal junction, B cell lymphoma, hepatocellular carcinoma and solid tumors. The drug candidate acts by targeting hematopoietic progenitor kinase 1 (HPK1). It is administered through oral route as capsules.

Nimbus Therapeutics overview

Nimbus Therapeutics, formerly Nimbus Discovery, is a biotechnology company that develops small molecule medicines to treat immunology, oncology and metabolic disorders. The company investigates TYK2 (tyrosine kinase 2) inhibitor targeting auto-immune disorders such as Crohn’s disease, psoriasis, multiple sclerosis and rheumatoid arthritis; HPK1 (hematopoietic progenitor kinase 1) inhibitor for the treatment of immuno-oncology diseases; ACLY (ATP citrate lyase), targeting cancer, metabolic and cardiovascular diseases; and AMPK (AMP-activated protein kinase) to treat metabolic disorders. Its pipeline programs include WRN (Werner syndrome helicase), a helicase used for treating microsatellite-instability (MSI) high tumors; Cbl-b (Casitas B-cell lymphoma), an E3 ubiquitin ligase, targeting immuno-oncology diseases; CTPS1 (CTP synthase 1) enzyme in lymphocytes to treat T and B cell-driven diseases. Nimbus Therapeutics is headquartered in Boston, Massachusetts, the US.

For a complete picture of NMBS-2’s drug-specific PTSR and LoA scores, buy the report here.

This content was updated on 10 June 2024

Data Insights


The gold standard of business intelligence.

Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.


GlobalData, the leading provider of industry intelligence, provided the underlying data, research, and analysis used to produce this article.

GlobalData’s Likelihood of Approval analytics tool dynamically assesses and predicts how likely a drug will move to the next stage in clinical development (PTSR), as well as how likely the drug will be approved (LoA). This is based on a combination of machine learning and a proprietary algorithm to process data points from various databases found on GlobalData’s Pharmaceutical Intelligence Center.